PT-141 (Bremelanotide) Research: MC4 Receptor Context
Overview
PT-141, the research name for bremelanotide, is a synthetic melanocortin-receptor agonist studied in in-vitro laboratory settings for its activity at MC1R, MC3R, and MC4R, with MC4 receptor signalling forming the primary mechanistic frame in the published literature. Research-grade material is not a regulated human medicine, and no clinical or therapeutic inference should be drawn from receptor-level findings alone.
Bremelanotide belongs to the α-MSH (alpha-melanocyte-stimulating hormone)/Melanotan II peptide family and is characterised by its receptor profile rather than by any single biological outcome. The MC4 receptor context matters because MC4R-linked pathways are central to neurobiological and endocrine signalling models, making PT-141 a defined tool compound for probing those systems in assay conditions. A result obtained in one cell line, species, or concentration range cannot be assumed to transfer to a different experimental system or to a different supplier’s material without independent analytical verification.
By reading this article, you will learn: how PT-141’s receptor binding profile defines its research identity; what the in-vitro, preclinical, and clinical evidence tiers each establish and where they diverge; and what analytical steps are required before committing a research-grade batch to an assay.
Key Takeaways
- PT-141 (bremelanotide) is a chemically defined synthetic peptide; its research identity is established by peptide sequence and molecular weight, not by trade name.
- MC4R is the receptor subtype most consistently associated with PT-141 in the published pharmacological literature, though binding activity at MC1R and MC3R is also documented.
- Evidence from in-vitro assays, preclinical rodent models, and clinical pharmaceutical trials represents three distinct tiers; findings from one tier do not transfer reliably to another.
- The 2019 US FDA approval of Vyleesi applies to a regulated pharmaceutical formulation, not to research-grade material; shared nomenclature does not imply equivalence.
- Batch-level analytical documentation, HPLC purity, mass spectrometry confirmation, and endotoxin data, is the minimum verification required before any assay begins.
Definition and Identity
PT-141, also called bremelanotide, is a synthetic cyclic heptapeptide and melanocortin-receptor agonist derived from the α-MSH family, studied in in-vitro settings for its activity at MC1R, MC3R, and MC4R, with MC4 receptor signalling forming the primary mechanistic frame in the published pharmacological literature.
Bremelanotide is classified as a melanocortin ligand, not a generic peptide label. Its research identity is defined by its receptor binding profile: MC4R is the subtype most consistently associated with central neurobiological signalling models in which PT-141 serves as a tool compound. Researchers sourcing PT-141 for in-vitro work should treat the names “PT-141” and “bremelanotide” as synonymous identifiers for the same chemically defined entity, confirmed by peptide sequence and molecular weight rather than by trade name alone.
The PT-141 20 mg Bremelanotide Pen product page provides the specific material and batch documentation relevant to sourcing decisions. Any claim about purity or structural equivalence to published bremelanotide requires batch-level analytical verification; understanding what HPLC purity does and does not prove is a necessary step before interpreting supplier-supplied chromatographic data.
Mechanism and Research Context
PT-141 (bremelanotide) acts as a functional agonist at melanocortin receptors, with MC4R representing the primary pharmacological target in central neurobiological research models. Binding to MC4R activates adenylyl cyclase via Gs-protein coupling, elevating intracellular cyclic AMP (cAMP) concentrations and initiating downstream signalling cascades in neural and endocrine cell systems, a cause-and-effect relationship that makes MC4R the central reference point for interpreting bremelanotide’s activity in assay data.
MC4R Signalling as the Research Frame
In in-vitro assay systems, bremelanotide serves as a tool compound to probe MC4R-linked cAMP responses, receptor occupancy, and pathway kinetics. The receptor’s expression in hypothalamic and limbic regions makes it a target of interest in neurobiological models examining energy regulation and autonomic signalling. Any interpretation of results depends strictly on the cell line, species origin, receptor expression level, and concentration range used in the specific assay; mechanistic claims that hold in one overexpressing cell-line model do not transfer to a different experimental system.
PT-141 also shows binding activity at MC1R and MC3R, but the published pharmacological literature most consistently frames bremelanotide within MC4R-centred discussion. Researchers should treat receptor selectivity as assay-dependent rather than absolute: the relative affinity profile reported in one study reflects that study’s conditions, not a universal property of every research-grade batch.
Because receptor activity is concentration- and purity-sensitive, confirming the analytical identity of the material used matters before any mechanistic interpretation is attempted. Researchers can verify a batch against its CoA to confirm that the peptide sequence and purity data align with the published bremelanotide reference before designing assays. Consulting storage and stability guidance for research peptides is relevant at this stage, since degradation can alter the receptor-binding profile of a peptide and confound mechanistic results.
What the Evidence Shows
The published evidence positions bremelanotide as a characterised melanocortin agonist with documented receptor-level activity, but the strength and scope of that evidence varies considerably across experimental tiers.
In-Vitro and Receptor-Level Evidence
At the receptor level, the most consistent body of work concerns MC4R binding and the downstream cAMP signalling cascade. Cell-based assays using heterologous expression systems, for example, HEK293 cells transfected with human MC4R, have demonstrated that bremelanotide acts as a functional agonist at MC4R, producing measurable intracellular responses under controlled conditions. This tier of evidence is the most reproducible because the variables, receptor density, cell line, ligand concentration, can be defined precisely. Researchers sourcing PT-141 for in-vitro work should consult the peptide research glossary for definitions of assay-specific terms such as EC₅₀ (the concentration producing half-maximal effect), receptor occupancy, and functional selectivity before interpreting published binding data.
Preclinical Evidence
Preclinical studies, predominantly in rodent models, have examined bremelanotide in the context of melanocortin-linked autonomic and neuroendocrine pathways. Results from this tier are model-specific: the species, receptor expression profile, and route of administration all affect the observed outcome, which is why findings from one rodent model do not replicate predictably in a different species or tissue preparation.
Clinical Evidence
The clinical evidence base is distinct from research-grade use. Bremelanotide received US Food and Drug Administration (FDA) approval in 2019 under the brand name Vyleesi for a specific indication in premenopausal adults; that approval applies to a regulated pharmaceutical formulation, not to research-grade material. No equivalence between a regulated medicinal product and a research-grade batch should be inferred from shared active-substance nomenclature. Researchers evaluating PT-141 as a tool compound should treat the clinical literature as contextual background rather than as evidence of what a given research batch will produce in a specific assay.
Evidence Limitations
Three distinct evidence tiers apply to bremelanotide research: in-vitro receptor assays, preclinical animal models, and clinical pharmaceutical data. Findings do not transfer reliably across tiers because the variables that govern outcome, receptor density, cell background, ligand concentration, species, and assay endpoint, differ between them. Each published finding should be treated as model-specific rather than as a general property of PT-141 as a compound class.
Generalisability Limits
The bremelanotide literature frequently mixes receptor pharmacology with clinical discussion, which creates a risk of conflating what the molecule does in a controlled assay with what a regulated pharmaceutical formulation does in a human trial. The 2019 US FDA approval of Vyleesi applies to a specific medicinal product under defined manufacturing standards; no equivalence to a research-grade batch follows from shared nomenclature. Reviewing what HPLC purity does and does not prove is a necessary step before interpreting any chromatographic data supplied with a research batch.
Batch-Level Uncertainty
General literature claims about bremelanotide purity or potency do not describe any specific supplier’s material. The identity, sequence confirmation, and chromatographic profile of a given batch are the only evidence relevant to that batch. Researchers should verify a batch against its CoA before committing it to an assay, because batch-number matching is the minimum check that connects a published analytical result to the physical material received.
Comparison with Related Compounds
PT-141 (bremelanotide) is most usefully compared with Melanotan II, because both are synthetic melanocortin-pathway peptides and PT-141 is generally treated as a derivative within that family. The practical distinction is receptor emphasis: PT-141 is presented in the literature as MC4-focused, whereas Melanotan II is discussed as a broader melanocortin agonist prototype with activity spanning MC1R through to MC4R, including MC1R-mediated pigmentation pathways.
PT-141 versus Melanotan II
| Criterion | PT-141 (Bremelanotide) | Melanotan II |
|---|---|---|
| Primary receptor framing | MC4R-centred | Broader MC1R–MC4R activity |
| Research identity | Bremelanotide; chemically defined synthetic peptide | Synthetic α-MSH analogue |
| Regulatory context | Active substance in Vyleesi (US FDA, 2019); research-grade material is distinct | No approved medicinal product as of 2026 |
| Typical research use | MC4R signalling and central pathway studies | Melanocortin receptor pharmacology broadly |
Researchers should also distinguish PT-141 from any authorised medicinal product containing bremelanotide as its active substance. Regulatory status and manufacturing standards for a licensed medicine differ from those of a research-grade batch; shared nomenclature does not imply equivalence. Consult the peptide research glossary for definitions of terms such as agonist, receptor selectivity, and assay that underpin this comparison.
Material Identity and Analytical Context
For PT-141 research use, material identity is established by analytical documentation, not by product name alone. A batch of PT-141 (bremelanotide) should be verified against its peptide sequence, stated molecular weight, chromatographic purity figure, and any accompanying mass spectrometry or HPLC (high-performance liquid chromatography) data before it is committed to an assay. Without batch-level documents, any supplier claim about purity or structural equivalence to published bremelanotide remains unverified.
What Analytical Methods Can and Cannot Establish
HPLC purity data confirms the proportion of the target compound relative to detectable impurities under the specific chromatographic conditions used; it does not confirm biological activity, receptor selectivity, or equivalence across different assay systems. Mass spectrometry confirms molecular mass and, where fragmentation data is included, sequence identity. Neither method alone establishes that a given batch will behave identically to the bremelanotide characterised in a published receptor-binding study, because experimental outcomes depend on the cell line, buffer conditions, and concentration range used in that study.
Veyvora states that each research-peptide batch is checked by two independent laboratories using HPLC, mass spectrometry, and endotoxin assay, with a published batch-level certificate of analysis (CoA). Researchers should request and review that certificate before use. For a fuller account of what chromatographic purity data can and cannot prove, see what HPLC purity does and does not prove.
Research-Use-Only Boundary
PT-141 (bremelanotide) supplied as a research peptide is not a medicinal product and must not be treated as one. Research-grade material is manufactured and quality-controlled to support in-vitro laboratory work; it is not produced under the Good Manufacturing Practice (GMP) standards that govern medicines supplied for human use, even where the active substance name is identical to that of an authorised product.
Researchers sourcing PT-141 for in-vitro assays should confirm three things before committing a batch to an experiment: that the supplier provides a batch-specific CoA; that the certificate includes HPLC purity, mass spectrometry confirmation, and endotoxin data; and that the batch number on the certificate matches the vial received. To verify a batch against its CoA, follow the procedural steps on that page before any assay begins.
Once material identity is confirmed, correct storage becomes the next critical variable, because peptide degradation between receipt and use can invalidate results independently of initial purity. Review storage and stability guidance for research peptides for the site’s current 2–8 °C handling requirements before logging the batch into your inventory.
To source the specific material discussed throughout this article, visit the PT-141 20 mg Bremelanotide Pen product page, where current batch documentation and pricing are listed.
